Showing results (71-80 of 253) with videos related to

Sort By:
Pageof 26
JAMA Oncology|September 24, 2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysisSmith Giri, Alyssa Grimshaw, Susan Bal, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
American Journal of Hematology|August 18, 2020
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myelomaBrian G M Durie, Shaji K Kumar, Saad Z Usmani, et al.
BMC Cancer|November 11, 2020
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaRafael Fonseca, Saad Z Usmani, Maneesha Mehra, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Leukemia & Lymphoma|July 19, 2021
Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studySamer Al Hadidi, Deepa Dongarwar, Hamisu M Salihu, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 19, 2020
Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based RegimensJai N Patel, Myra Robinson, Megan Jagosky, et al.
Haematologica|June 13, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agentsSaad Z Usmani, Christoph Heuck, Alan Mitchell, et al.
Clinical Case Reports|April 4, 2015
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocolsZeba N Singh, Yogesh Jethava, Ginell R Post, et al.
Oncology and Therapy|June 4, 2023
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple MyelomaStephen Palmer, Yi Lin, Thomas G Martin, et al.
Pageof 26